MedTrace Logo

A Study of ddI in Patients With AIDS Who Become Sicker While Taking Zidovudine

NCT00002274 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL

Last updated 2007-10-02

No results posted yet for this study

Summary

The objective of this open-label study regimen is to make didanosine (ddI) available to patients with AIDS who are clinically deteriorating on zidovudine (AZT) and cannot enter the Phase II ddI programs due to protocol exclusion or geographic location.

Conditions

  • HIV Infections
  • Leukoencephalopathy, Progressive Multifocal

Interventions

DRUG

Didanosine

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002274 on ClinicalTrials.gov